Martin Desrosiers

Martin Desrosiers

Auto-generated profile, based on publicly available information

Martin Desrosiers

Division of Otolaryngology Head and Neck Surgery Centre Hospitalier de L'université De Montréal University of Montreal Montreal Quebec Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
CBClaus Bachert
Claus Bachert
NBNeil Bhattacharyya
Neil Bhattacharyya
MDMartin Desrosiers
Martin Desrosiers
AKAsif H Khan
Asif H Khan
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammation-mediated disease of the nasal mucosa and paranasal sinuses with an under-recognized clinical, humanistic, and economic burden. Patients with CRSwNP experience a high symptom burden, including nasal congestion, loss of smell, and rhinorrhea, which has a negative impact on physical and mental health-related quality of life, including sleep quality. Existing medical and surgical interventions, including local and systemic corticosteroids and endoscopic sinus surgery, may be associated with recurrence of nasal polyps and associated symptoms and with an increased risk of short- and long-term adverse effects, especially with repeated or long-term use. Because type 2 inflammation is implicated in the pathogenesis of several coexisting diseases, patients with CRSwNP often have comorbid asthma and/or nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. These patients, as well as those with high corticosteroid use and/or sinonasal surgical history, have more severe disease and associated symptom burden and represent a difficult-to-treat population under the existing management paradigm. This article reviews the clinical, humanistic, and economic burden of CRSwNP; it highlights the unmet need for effective and safe CRSwNP therapies that effectively control symptoms and minimize recurrence by targeting the underlying type 2 inflammatory disease pathophysiology.

10 February 2011 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
MDMartin Desrosiers
Martin Desrosiers
GEGerald A Evans
Gerald A Evans
PKPaul K Keith
Paul K Keith
EWErin D Wright
Erin D Wright
AKAlan Kaplan
Alan Kaplan
IWIan J Witterick
Ian J Witterick
This document provides healthcare practitioners with information regarding the management of acute rhinosinusitis (ARS) and chronic rhinosinusitis (CRS) to enable them to better meet the needs of this patient population. These guidelines describe controversies in the management of acute bacterial rhinosinusitis (ABRS) and include recommendations that take into account changes in the bacteriologic landscape. Recent guidelines in ABRS have been released by American and European groups as recently as 2007, but these are either limited in their coverage of the subject of CRS, do not follow an evidence-based strategy, or omit relevant stakeholders in guidelines development, and do not address the particulars of the Canadian healthcare environment.

10 January 2014 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
LELeandra Mfuna Endam
Leandra Mfuna Endam
AFAbdelali Filali‐Mouhim
Abdelali Filali‐Mouhim
PBPierre Boisvert
Pierre Boisvert
LBLouis‐Philippe Boulet
Louis‐Philippe Boulet
YBYohan Bossé
Yohan Bossé
MDMartin Desrosiers
Martin Desrosiers

1 June 2012 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
PKPAUL KEVIN KEITH
PAUL KEVIN KEITH
MDMartin Desrosiers
Martin Desrosiers
TLTina Laister
Tina Laister
RSR Robert Schellenberg
R Robert Schellenberg
SWSusan Waserman
Susan Waserman
Allergic rhinitis (AR) is a common problem and we sought to examine the burden of disease and its management in Canada from the perspectives of patients and physicians.

1 March 2007 in American Journal of Rhinology
Verified
Journal Article
Closed access
MDMartin Desrosiers
Martin Desrosiers
ZBZohra Bendouah
Zohra Bendouah
JBJean Barbeau
Jean Barbeau
Background: In vitro biofilm-producing capacity in isolates of Staphylococcus aureus and Pseudomonas aeruginosa collected from the sinus cavities after endoscopic sinus surgery (ESS) are associated with a poor outcome in patients with chronic rhinosinusitis (CRS). However, conventional oral antibiotic therapy is frequently ineffective in eradicating bacteria in the biofilm form. Increasing the concentration of antibiotics may offer a means of countering this resistance. The aim of this study was to determine the in vitro activity of moxifloxacin (MOXI) against S. aureus in biofilm form (recovered from patients with CRS at least 1 year post-ESS). Method: This study was performed in a research microbiology laboratory, where five isolates of S. aureus with known biofilm-forming capacity were cultured in Tryptic Soy Broth 0.5% glucose in 96-well plates at 37°C for 24 hours. After visual confirmation of biofilm formation, plates were incubated in phosphate-buffered saline (PBS) or with MOXI at concentrations of 0.1×, 1×, 100×, and 1000× minimal inhibitory concentration (MIC) for an additional 24 hours. Biofilm from 3 wells of each concentration were collected and sonicated and the number of viable bacteria was determined by serial dilution and plating. Results: After incubation, the number of viable bacteria was similar for nontreated and MOXI-treated biofilms at MIC and sub-MIC levels. However, MOXI at 1000× (0.1–0.2 mg/mL) gave a 2 to 2.5 log reduction in number of viable bacteria. Conclusion: In vitro results show that increased concentrations of antibiotics, easily attainable in topical solutions, are effective in killing bacteria in bacterial biofilms. This suggests a role for topical antibiotic therapies in the treatment of biofilm infections.

15 February 2010 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
LELeandra Mfuna Endam
Leandra Mfuna Endam
CCChantale Cormier
Chantale Cormier
YBYohan Bossé
Yohan Bossé
AFAbdelali Filali-Mouhim
Abdelali Filali-Mouhim
MDMartin Desrosiers
Martin Desrosiers
Research from JAMA Otolaryngology–Head & Neck Surgery — Association of IL1A, IL1B, and TNF Gene Polymorphisms With Chronic Rhinosinusitis With and Without Nasal Polyposis — A Replication Study